End Of Review Meeting, Maximum Expected Number Of Days After Request For Meeting

No definition available.

Name:	apri_EndOfReviewMeetingMaximumExpectedNumberOfDaysAfterRequestForMeeting
Namespace Prefix:	apri_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Fees, Potential Future Milestone Payments Receivable

+ References

No definition available.

+ Details

Name:	apri_LicenseFeesPotentialFutureMilestonePaymentsReceivable
Namespace Prefix:	apri_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=apri_AllerganformerlyWarnerChilcottMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=apri_VitarosMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Allergan In-Licensing Agreement (FY) (Details) - USD ($) $ in Millions	1 Months Ended
	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2015	Sep. 30, 2018	Dec. 31, 2017
Forecast
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum expected number of days from request to end-of-review meeting	30 days
Allergan \| Vitaros
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License cost payments			$ 1.0
Payments to Allergan, research and development		$ 1.5	$ 1.0
License fees, potential future milestone payments receivable				$ 25.0	$ 25.0